Life Sciences

  • April 24, 2026

    Up Last At High Court: TPS, Geofence, Skinny Labels

    The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.

  • April 24, 2026

    Natera Tells Justices CareDx Made Up Circ. Split In Petition

    Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."

  • April 24, 2026

    NY Court Pauses $100M Saudi Arabia Pharma Award Suit

    A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.

  • April 24, 2026

    What's At Stake As High Court Hears Roundup Appeal

    With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.

  • April 24, 2026

    Danaher Execs Face Investor Suit Over Post-COVID Outlook

    Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.

  • April 24, 2026

    Merck's $6.7B Terns Deal Clears Regulatory Hurdle

    Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday. 

  • April 24, 2026

    Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial

    Pfizer and Israeli generic-drug maker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.

  • April 24, 2026

    Biotechs Clash Over Cancer Drug Discovery In Chancery

    AnaptysBio and Tesaro, alongside Tesaro parent GlaxoSmithKline LLC, sparred Friday in the Delaware Chancery Court over the scope of discovery in the biotechnology firms' contract fight regarding cancer drug Jemperli, with each side accusing the other of trying to tilt the evidentiary record ahead of a fast-approaching trial in July.

  • April 24, 2026

    Taxation With Representation: Gibson Dunn, Paul Weiss

    In this week's Taxation With Representation, Elon Musk's SpaceX strikes a deal with Cursor that could lead to an acquisition of the artificial intelligence startup, building products distributor QXO Inc. buys TopBuild Corp., and Eli Lilly & Co. acquires clinical-stage biotechnology company Kelonia Therapeutics.

  • April 23, 2026

    Latest Squires Order Grants 5 IPRs, Denies 4 On The Merits

    U.S. Patent and Trademark Office Director John Squires granted five America Invents Act patent challenges and denied four others in his latest bulk order making institution decisions with little commentary.

  • April 23, 2026

    Full Fed. Circ. Urged To Rethink Corcept Patent Loss

    Corcept Therapeutics Inc. wants the Federal Circuit to rethink a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying the panel improperly relied on a ruling from a 2022 case.

  • April 23, 2026

    FTC Cuts Deal To End Anesthesia Group Rollup Case

    The Federal Trade Commission reached an agreement Thursday to settle its case accusing U.S. Anesthesia Partners Inc. of monopolizing the Texas anesthesia services market by purchasing most of the competing anesthesia practices in the state.

  • April 23, 2026

    Pa. County Joins Insulin-Pricing Suit Blitz Against CVS, PBMs

    Chester County, Pennsylvania, filed its own suit in a sprawling multidistrict litigation against CVS and multiple pharmacy benefit managers and drug companies, claiming the entities worked together to inflate the price of insulin.

  • April 23, 2026

    Kirkland To Add Tenn. SG Behind Skrmetti Supreme Court Win

    The Tennessee solicitor general, who successfully defended the state's ban on some gender-affirming care for minors before the U.S. Supreme Court, will join the Nashville office of Kirkland & Ellis, the firm announced Thursday. 

  • April 23, 2026

    Firm Seeking Philly Zantac Judge's Recusal Appeals Refusal

    A plaintiff represented by Keller Postman LLC has asked the Pennsylvania Superior Court to weigh in on a Philadelphia judge's refusal to recuse himself from overseeing mass tort litigation against GlaxoSmithKline over Zantac's alleged cancer risks.

  • April 23, 2026

    ITC Investigating Chinese Biopharma Chemicals Over Pricing

    The U.S. International Trade Commission is looking into whether Chinese imports of two chemicals used in biopharma manufacturing that are allegedly being sold at unfair prices are harming U.S. domestic industry, it said in a notice published Thursday.

  • April 23, 2026

    DOJ Says Medical Pot Shift Shouldn't Affect Gun Rights Case

    Despite an order from the U.S. Department of Justice loosening federal restrictions on medical marijuana, the Trump administration signaled Thursday that it does not intend for the changes to cannabis regulation to apply retroactively.

  • April 23, 2026

    Trulieve Says Infringement Suit Doesn't Actually State A Claim

    Cannabis company Trulieve Inc. has said a rival company's complaint against it lacks any factual basis to support the allegation Trulieve infringed the rival's patents, urging a Florida federal court to throw out the suit.

  • April 23, 2026

    DOJ Final Order Loosens Rules For State-Legal Medical Pot

    The U.S. Department of Justice published a final order Thursday loosening federal restrictions on medical marijuana products that fall within the ambit of state-regulated programs or have approval from the U.S. Food and Drug Administration.

  • April 22, 2026

    Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid

    The full Federal Circuit on Wednesday rejected Sarepta Therapeutics Inc.'s bid for a rehearing after a panel's decision revived a University of Pennsylvania gene therapy patent that is licensed by clinical-stage biotechnology company Regenxbio Inc.

  • April 22, 2026

    Bayer 'Natural' Vitamin Buyer Classes Affirmed By 9th Circ.

    A split Ninth Circuit on Tuesday upheld a federal district court's certification of New York and California classes of consumers who bought Bayer Healthcare multivitamin gummies that were allegedly labeled falsely as "natural," finding the company "demands more" from the plaintiffs at this stage of the litigation than certification requires. 

  • April 22, 2026

    Eli Lilly Case Over Weight Loss Drugs Kept Mostly Intact

    A California federal court has refused to throw out a lawsuit from Eli Lilly against a telehealth company and related entities over the compounding of its popular weight loss drugs Mounjaro and Zepbound, but agreed to trim a conspiracy claim from the case.

  • April 22, 2026

    Justices Would Back Vax Law Challenge, 2nd Circ. Told

    The U.S. Supreme Court's March 2 decision in a California gender-related school policy case requires the Second Circuit to advance a 2023 challenge to Connecticut's preschool and daycare student vaccine mandates, an attorney for a Constitution State congregation told a three-judge panel on Wednesday.

  • April 22, 2026

    Judge Lets Pharma Co. Seal Parts Of Ex-GC's Retaliation Suit

    A Texas state judge on Wednesday granted Houston-based Empower Clinic Services LLC's bid to permanently and partially seal a petition by its former general counsel that alleges a smear campaign by the company after he confronted them about conduct he said was unlawful.

  • April 22, 2026

    Sorrento, M3 Get Pause On RICO Suit Naming Jackson Walker

    A Texas bankruptcy judge on Wednesday agreed to put on hold a lawsuit in California federal court alleging Jackson Walker LLP and executives at Sorrento Therapeutics and M3 Partners conspired to forum shop in Texas so the drug developer could seek Chapter 11 protection there.

Expert Analysis

  • How Cos. Should Prepare For Prop 65 Listing Of Bisphenols

    Author Photo

    California regulators are moving toward classifying all p,p'-bisphenol chemicals as causing reproductive toxicity under Proposition 65, which could require warning notices for a vast range of consumer and industrial products, and open the floodgates to private litigation — so companies should proactively review their suppy chains, says Gregory Berlin at Alston & Bird.

  • Rule Amendments Pave Path For A Privilege Claim 'Offensive'

    Author Photo

    Litigators should consider leveraging forthcoming amendments to the Federal Rules of Civil Procedure, which will require early negotiations of privilege-related discovery claims, by taking an offensive posture toward privilege logs at the outset of discovery, says David Ben-Meir at Ben-Meir Law.

  • IP Ownership Risk Grows In Booming Cancer Drug Market

    Author Photo

    The ownership of intellectual property has become strategically decisive in deals involving valuable cancer therapeutics known as ADCs, as highlighted by the recent Takeda-Innovent deal, with the commercial value of a license resting on the integrity and defensibility of the underlying technology, say attorneys at Loeb & Loeb.

  • Series

    My Miniature Livestock Farm Makes Me A Better Lawyer

    Author Photo

    Raising miniature livestock on my farm, where I am fully present with the animals, is an almost meditative time that allows me to return to work invigorated, ready to juggle numerous responsibilities and motivated to tackle hard issues in new ways, says Ted Kobus at BakerHostetler.

  • Surveying The Healthcare Policy Landscape Post-Shutdown

    Author Photo

    With last week's agreement to reopen the federal government, at least through the end of January, key healthcare legislation that has been in limbo since a December 2024 spending bill fell apart may recapture the attention of Congress, say attorneys at Faegre Drinker.

  • FDA Biosimilar Guidance Should Ease Biologics Development

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, indicating that the agency may no longer routinely require comparative efficacy studies when other evidence provides sufficient assurance of biosimilarity, underscores the FDA's trust in analytical technology as a driver of biologics access, say attorneys at Hogan Lovells.

  • Litigation Funding Could Create Ethics Issues For Attorneys

    Author Photo

    A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.